ReviewImmunotherapy2025
Biology-driven therapies of CAR T immune effector cell-associated neurotoxicity syndrome.
Review in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Persistent parkinsonism with dopaminergic denervation following axicabtagene ciloleucel therapy for diffuse large B cell lymphoma: a case report.International journal of hematology · 2026Article
- Cytokine-Engineered Chimeric Antigen Receptor-T Cell Therapy: How to Balance the Efficacy and Toxicity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR) T cell therapy, particularly CD19-directed CAR T cells, can induce immune effector cell-associated neurotoxicity syndrome (ICANS), leading to significant morbidity and the need for immunosuppressive treatment. In this review, we discuss the molecular mechanisms leading to ICANS, drawing insights from various preclinical models and translational studies. We discuss pathophysiologic insights of ICANS from B-cell lymphoma-bearing mouse models, highlighting key differences between syngeneic and xenogeneic systems. Additionally, we review diagnostic methods to detect ICANS such as MRI, CSF analyses, and translocator-protein-positron-emission-tomography (TSPO-PET). Furthermore, we summarize current treatment recommendations and emerging therapeutic strategies aimed at mitigating ICANS. In summary, we provide a comprehensive overview of ICANS-pathophysiology, diagnostic approaches, and treatment interventions, with a focus on controlling immune dysregulation to prevent neurological complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.